医学
V600E型
突变
甲状腺癌
癌症研究
甲状腺乳突癌
肿瘤科
甲状腺癌
癌症
危险系数
内科学
基因
甲状腺
遗传学
生物
置信区间
作者
Nobuyuki Bandoh,Takashi Goto,Yasutaka Kato,Akinobu Kubota,Shota Sakaue,Ryuhei Takeda,Shuto Hayashi,Mio Hayashi,Shogo Baba,Tomomi Yamaguchi‐Isochi,Hiroshi Nishihara,Hajime Kamada
标识
DOI:10.1016/j.asjsur.2023.09.049
摘要
The aim of this study was to evaluate the correlation among mutations in cancer-related genes, clinicopathologic features, and clinical outcome in classical papillary thyroid carcinoma (PTC). A total of 130 patients with classical PTC who underwent curative surgery between April 2012 and June 2023 at Hokuto Hospital were included. Mutations in targeted regions of 160 cancer-related genes were detected by next-generation sequencing (NGS)-based cancer panel testing. The BRAF V600E mutation was detected in 108 (83.1%) of 130 PTC patients. Among the 108 patients with the BRAF V600E mutation, other co-existing oncogenic mutations were found in 12 (9.2%) patients. When we divided into 3 groups of no mutations, BRAF V600E mutation alone, and BRAF V600E and other oncogenic mutations, significant differences were observed in terms of tracheal invasion (P = 0.0024), and bilateral neck lymph node metastasis (P = 0.0047). Kaplan–Meier analysis of overall survival (OS) revealed patients with BRAF V600E and other oncogenic mutations had significantly poorer survival than those with BRAF V600E mutation alone (P = 0.0026). Multivariate cox proportional hazard analysis revealed BRAF V600E and other oncogenic mutations was an independent prognostic factor for OS (HR: 10.559; 95%CI: 1.007-110.656, P = 0.0493). The BRAF V600E mutation co-existing with other oncogenic mutations but not the BRAF V600E mutation alone was associated with aggressive clinicopathologic features, resulting in poor prognosis in patients with classical PTC. Detection of oncogenic mutations using NGS-based cancer panel testing could enhance understanding of the clinical features of classical PTC.
科研通智能强力驱动
Strongly Powered by AbleSci AI